On Aug. 27, 2020, Pfizer and Shanghai Fosun Pharmaceutical announced an intended collaboration to supply 10 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, subject to clinical success and regulatory approval, to Hong Kong and Macao.